C. Fletcher, K. Unni, and M. F. Lyon, World Health Organization, Kleihues P, Sobin LH (Series Editors): World Health Organization Classification of Tumors], pp.234-257
DOI : 10.4135/9781483345758.n642

C. Velasco, S. Colliec-jouault, F. Redini, D. Heymann, and M. Padrines, Proteoglycans on bone tumor development, Drug Discovery Today, vol.15, issue.13-14, pp.13-14553, 2010.
DOI : 10.1016/j.drudis.2010.05.009

E. Miot-noirault, F. Gouin, A. Vidal, M. Rapp, J. Maublant et al., First Preclinical Imaging of Primary Cartilage Neoplasm and Its Local Recurrence Using 99mTc-NTP 15-5 Radiotracer, Journal of Nuclear Medicine, vol.50, issue.9, pp.1541-1547, 2009.
DOI : 10.2967/jnumed.108.056721

A. Onishi, A. Hincker, and F. Lee, Surmounting Chemotherapy and Radioresistance in Chondrosarcoma: Molecular Mechanisms and Therapeutic Targets, Sarcoma, vol.3, issue.6, p.381564, 2011.
DOI : 10.1016/j.ijrobp.2008.12.055

G. Moriceau, B. Ory, B. Gobin, F. Verrecchia, F. Gouin et al., Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.2981-2987, 2010.
DOI : 10.2174/138161210793563554
URL : https://hal.archives-ouvertes.fr/inserm-00511241

F. Gouin, B. Ory, F. Rédini, and D. Heymann, Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival, International Journal of Cancer, vol.43, issue.5, pp.980-984, 2006.
DOI : 10.1002/ijc.21951

A. Streitbuerger, M. Henrichs, H. Ahrens, C. Lanvers-kaminzky, F. Gouin et al., Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78, International Orthopaedics, vol.119, issue.5, pp.1369-1373, 2011.
DOI : 10.1007/s00264-010-1130-5

E. Grimaud, C. Damiens, A. Rousselle, N. Passuti, D. Heymann et al., Bone remodelling and tumor grade modifications induced by interactions between bone and swarm rat chondrosarcoma, Histol Histopathol, vol.17, pp.1103-1111, 2002.

G. Odri, S. Dumoucel, G. Picarda, S. Battaglia, F. Lamoureux et al., Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients, Cancer Research, vol.70, issue.19, pp.7610-7619, 2010.
DOI : 10.1158/0008-5472.CAN-09-4272

L. Montella, R. Addeo, V. Faiola, G. Cennamo, R. Guarrasi et al., Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, p.7, 2009.
DOI : 10.1186/1756-9966-28-7

E. Fox, S. Patel, J. Wathen, S. Schuetze, S. Chawla et al., Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003, The Oncologist, vol.17, issue.3, p.321, 2012.
DOI : 10.1634/theoncologist.2010-0265

A. Chiti and W. Oyen, Imaging of therapy response in oncology, Q J Nucl Med, vol.55, pp.587-588, 2011.

G. Arsos, I. Venizelos, N. Karatzas, A. Koukoulidis, and C. Karakatsanis, Low-grade chondrosarcomas: a difficult target for radionuclide imaging. Case report and review of the literature, European Journal of Radiology, vol.43, issue.1, pp.66-72, 2002.
DOI : 10.1016/S0720-048X(01)00427-2